First-line targeted therapy shows antitumor activity in patients with advanced lung cancer
First-line zongertinib showed antitumor activity in treatment-naïve patients with advanced or metastatic HER2-mutant non-small cell lung cancer (NSCLC), providing a safe and effective oral targeted treatment alternative to chemotherapy, according to researchers at The University of Texas MD Anderson Cancer Center.
Results from the multi-site Phase...
AACR: UT MD Anderson shares latest breakthroughs in cancer research
ABSTRACTS: NG05, 1296, 1297, 1361, 1366, 2709, 3451, 4010, 4020, 4033, 4053, 6724, 6743, 6761, 6788, 6803
Researchers from The...
Researchers find new target to sensitize pancreatic tumors to immunotherapy
Study identifies strategy to overcome radiation therapy resistance in lung cancer
In a preclinical study published today in Cancer Research, a journal of the American Association for Cancer Research, researchers at The University of Texas MD Anderson...
Researchers identify blood-based biomarker for cancer risk in people with Lynch Syndrome
Radiation therapy improves outcomes for 'supermassive’ bile duct tumors
Patient outcomes were significantly better when treated with radiation therapy plus standard-of-care chemotherapy
First-in-class radio-theranostic utilizes novel antibody developed at UT MD Anderson
Study details the development of a novel antibody that targets a specific type of B7-H3, a protein overexpressed in many cancers
Combination treatment benefits patients with advanced breast cancer that has spread to brain
Leptomeningeal metastasis occurs when cancer spreads to the thin layers of tissue and fluid that surround...
Dual targeting approach improves immunotherapy response in glioblastoma
Researchers from The University of Texas MD Anderson Cancer Center have found that simultaneously blocking two key “don’t eat me signals”...
Low testosterone levels may be associated with increased risk of prostate cancer progression during surveillance
Study found men with low testosterone levels were associated with a 60% higher likelihood that prostate cancer...
New biomarker predicts chemotherapy response in triple-negative breast cancer
Antibody-drug conjugate achieves high response rates as frontline treatment in aggressive, rare blood cancer
Biomarkers predict patients with glioblastoma who will survive longer after treatment with cancer-targeting virus
First-in-human study finds novel immune cell therapy is safe and effective in advanced lymphoma
Americans prefer to screen for cervical cancer in-clinic vs. at home
Study shows strong evidence for effectiveness of metastasis-directed radiation therapy in prostate cancer
Blood biomarker points to increased risk of brain metastasis in patients with inflammatory breast cancer
Study reveals synergistic effect of CDK2 and CDK4/6 combination therapy
Engineered nanobodies improved respiratory defenses in preclinical study
Immune-targeting vaccine shows promise intercepting cancer in patients with Lynch Syndrome
New treatment combination offers excellent results for early-stage Hodgkin lymphoma with less chemotherapy
More than 90% of patients had a complete response to novel treatment combination
After two years, 97% of patients remained...
Novel immunotherapy demonstrates early potential to overcome resistance to immune checkpoint therapy
Mutation predicts chemotherapy resistance and better responses to immunotherapy in advanced bladder cancer
Higher bacteria levels inside tumors can promote immunotherapy resistance in head and neck cancer
Researchers found that the amount, and not the type, of bacteria inside tumors can predict response to treatment in lab...
Dual-antigen targeting of large B-cell lymphoma shows promise in reducing relapse
Large B-cell lymphoma (LBCL) is an aggressive blood cancer with few treatment options
CAR T cell therapy targeting...
Immunotherapy before and after surgery improved outcomes in lung cancer patients with lymph node metastases
Perioperative nivolumab plus neoadjuvant chemotherapy improved outcomes for patients regardless of...
Immunotherapy combination does not improve outcomes for patients with advanced anal cancer
Researchers identify novel therapeutic target to improve recovery after nerve injury
High levels of protein drive tumor immune suppression in head and neck cancer
Targeted therapy plus immunotherapy improved outcomes in advanced metastatic colorectal cancer